ArticleFrontiers in pharmacology2025
Modulation of TNFα-driven neuroinflammation by Gardenin A: insights from
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic alcohol consumption is a major contributor to neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption, leading to significant neuronal injury. Traditional therapies for alcohol use disorder (AUD) predominantly target behavioral and receptor-based mechanisms, often neglecting the direct pathophysiological impacts of alcohol on brain tissue. This study explores the neuroprotective potential of Gardenin A (GarA), a hexa-methoxylated flavone, in counteracting alcohol-induced inflammation and physiological damage. Methods: Results: The treatment with GarA resulted in enhanced neuronal viability and a reduction in ethanol-induced oxidative stress Discussion: GarA demonstrates neuroprotective potential, with evidence suggesting modulation of neuroinflammation and oxidative stress that may involve TNFα and BDNF pathways. These promising findings suggest potential therapeutic applications for GarA in addressing alcohol-related neurodegeneration. Future research focusing on clinical trials may prove helpful in validating these preclinical findings. Expanding studies to include diverse animal models and exploring combinatory treatments with existing AUD therapies could enhance understanding and application. Such efforts may pave the way for incorporating GarA into comprehensive pharmacotherapeutic strategies aimed at mitigating the neuropathological effects of chronic alcohol consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.